Selected Publications

• article

  1. Association of GLP-1 inhibitors with cardiovascular outcomes in patients undergoing coronary artery bypass surgery..  The Journal of thoracic and cardiovascular surgery.  2026
  2. Extracting Cognitive Impairment Assessment Information From Unstructured Notes in Electronic Health Records Using Natural Language Processing Tools: Validation with Clinical Assessment Data..  Clinical epidemiology.  353-365. 2025
  3. Comparative ranking of marginal confounding impact of natural language processing-derived versus structured features in pharmacoepidemiology..  Computers in biology and medicine.  -. 2025
  4. Generalizability of Clinical Trials of Novel Weight Loss Medications to the US Adult Population..  JAMA internal medicine.  185:108-110. 2025
  5. Development and Validation of an Intracranial Hemorrhage Risk Score in Older Adults with Atrial Fibrillation Treated with Oral Anticoagulant..  Clinical epidemiology.  267-279. 2024
  6. The impact of using reinforcement learning to personalize communication on medication adherence: findings from the REINFORCE trial..  NPJ digital medicine.  7:-. 2024
  7. Identifying Functional Status Impairment in People Living With Dementia Through Natural Language Processing of Clinical Documents: Cross-Sectional Study..  Journal of medical Internet research.  -. 2024
  8. Development and Validation of a Claims-Based Model to Predict Categories of Obesity..  American journal of epidemiology.  193:203-213. 2024
  9. Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral Anticoagulants..  JAMA network open.  6:-. 2023
  10. Improving the accuracy of automated gout flare ascertainment using natural language processing of electronic health records and linked Medicare claims data..  Pharmacoepidemiology and drug safety.  33:-. 2023
  11. Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results..  Clinical pharmacology and therapeutics.  114:853-861. 2023
  12. The impact of electronic health record discontinuity on prediction modeling..  PloS one.  18:-. 2023
  13. Common non-cardiovascular multimorbidity groupings and clinical outcomes in older adults with major cardiovascular disease..  Journal of the American Geriatrics Society.  71:3179-3188. 2023
  14. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials..  JAMA.  329:1376-1385. 2023
  15. Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets..  Clinical epidemiology.  349-362. 2023
  16. A Novel Chronic Kidney Disease Phenotyping Algorithm Using Combined Electronic Health Record and Claims Data..  Clinical epidemiology.  299-307. 2023
  17. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation..  JAMA network open.  6:-. 2023
  18. Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization..  JAMA network open.  6:-. 2023
  19. Scalable Feature Engineering from Electronic Free Text Notes to Supplement Confounding Adjustment of Claims-Based Pharmacoepidemiologic Studies..  Clinical pharmacology and therapeutics.  113:832-838. 2023
  20. Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020..  JAMA network open.  5:-. 2022
  21. Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care..  American heart journal.  203-215. 2022
  22. Understanding variation in the results of real-world evidence studies that seem to address the same question..  Journal of clinical epidemiology.  161-170. 2022
  23. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease..  Annals of internal medicine.  175:W4-W5. 2022
  24. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data..  Pharmacoepidemiology and drug safety.  31:467-475. 2021
  25. REinforcement learning to improve non-adherence for diabetes treatments by Optimising Response and Customising Engagement (REINFORCE): study protocol of a pragmatic randomised trial..  BMJ open.  11:-. 2021
  26. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study..  Diabetes, obesity & metabolism.  24:442-454. 2021
  27. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes..  JAMA network open.  4:-. 2021
  28. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease..  Annals of internal medicine.  174:1528-1541. 2021
  29. Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study..  Annals of internal medicine.  174:1214-1223. 2021
  30. Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs..  ACR open rheumatology.  3:531-539. 2021
  31. Updating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty Index..  The journals of gerontology. Series A, Biological sciences and medical sciences.  76:1316-1317. 2021
  32. Validation of claims-based algorithms to identify patients with psoriasis..  Pharmacoepidemiology and drug safety.  30:868-874. 2021
  33. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults..  Diabetes care.  44:826-835. 2021
  34. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies..  BMJ (Clinical research ed.).  -. 2021
  35. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative..  Circulation.  143:1002-1013. 2020
  36. The associated press stylebook.  Substance abuse.  43:127-130. 2020
  37. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study..  BMJ (Clinical research ed.).  -. 2020
  38. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care..  Endocrinology, diabetes & metabolism.  3:-. 2019
  39. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care..  Circulation.  139:2822-2830. 2019